Cargando…
Hematopoietic Stem Cell Transplantation in Acute Promyelocytic Leukemia in the Era of All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (ATO)
SIMPLE SUMMARY: Acute promyelocytic leukemia (APL) currently benefits from first-line treatment based on all-trans retinoic acid and arsenic trioxide, ensuring long-term complete responses for most patients. However, a proportion of 5–20% of patients relapse, and their long-term survival, even in th...
Autores principales: | Colita, Andrei, Tanase, Alina Daniela, Tomuleasa, Ciprian, Colita, Anca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452822/ https://www.ncbi.nlm.nih.gov/pubmed/37627139 http://dx.doi.org/10.3390/cancers15164111 |
Ejemplares similares
-
All-trans-retinoic-acid and arsenic trioxide induced remission in promyelocytic blast crisis
por: Colvin, Teresa A., et al.
Publicado: (2018) -
Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial
por: Zhang, Xinxin, et al.
Publicado: (2018) -
Long-term control of refractory follicular lymphoma after treatment of secondary acute promyelocytic leukemia with arsenic trioxide (As(2)O(3)) and all-trans retinoic acid (ATRA)
por: Jain, Preetesh, et al.
Publicado: (2018) -
Progress in Hematopoietic Stem Cell Transplantation and Cellular Therapies
por: Cenariu, Diana, et al.
Publicado: (2022) -
Thrombocytosis in a patient with acute promyelocytic leukemia during treatment with all‐trans retinoic acid and arsenic trioxide
por: Habibi, Maryam, et al.
Publicado: (2021)